Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Glioblastoma vaccines: past, present, and opportunities
Zujian Xiong
,
Itay Raphael
, Michael Olin
, Hideho Okada
, Xuejun Li
*
, Gary Kohanbash
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review article
›
peer-review
89
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Glioblastoma vaccines: past, present, and opportunities'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Glioblastoma
100%
Past-present
100%
Therapeutic Vaccine
60%
Monotherapy
40%
Clinical Efficacy
40%
Neoantigen
40%
Efficacy Improvement
40%
Standard of Care
20%
Immunization
20%
Tumor Antigen
20%
Chimeric Antigen Receptor T Cells (CAR-T)
20%
Design Strategy
20%
Peptide Drugs
20%
Vaccination Strategy
20%
Therapeutic Effect
20%
Vaccine Design
20%
Tumor Control
20%
Vaccine Potential
20%
Therapeutic Vaccination
20%
Central Nervous System Tumors
20%
Antigen Targeting
20%
Immune Checkpoint Blockade
20%
Target Current
20%
Vaccine Platform
20%
Mutation Burden
20%
Immunology and Microbiology
Immunotherapy
100%
Antigen
100%
Neoantigen
100%
Infectious Agent
50%
Tumor Antigen
50%
Central Nervous System
50%
Immune Checkpoint Blockade
50%
Tumor Vaccine
50%
Chimeric Antigen Receptor T-Cell Therapy
50%
Peptides
50%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Immunotherapy
40%
Monotherapy
40%
Antigen
40%
Therapeutic Vaccine
40%
Vaccination
40%
Infectious Agent
20%
Tumor Antigen
20%
Therapeutic Effect
20%
Central Nervous System Tumor
20%
Chimeric Antigen Receptor
20%
Tumor Vaccine
20%
Peptide
20%